Coloplast A/S (COLO B.CO) Stock Price
Coloplast A/S Price
Revenue has compounded at 7.8% per year over the past 19 years to 27.87 B DKK. Earnings per share have grown at 11.4% per year over the last 19 years. Coloplast A/S's net margin stands at 13.0%, down from 24.8% several years earlier. Coloplast A/S currently offers a dividend yield of about 5.49%. The payout ratio is around 142% of earnings. The dividend has grown at 19.3% per year over the past 19 years. Analysts set a median price target of 642.60 DKK, implying 53.4% above the current price. Of 27 analysts, 9 rate the stock a buy — an overall Hold consensus.
Coloplast A/S stock price
Coloplast A/S business model & stock analysis
Frequently asked questions about Coloplast A/S
The business model of Coloplast A/S revolves around developing and manufacturing medical devices and services that cater to the needs of individuals with intimate healthcare needs. As a leading global supplier, Coloplast focuses on urology, ostomy, continence, wound care, and skin care products. By constantly innovating and collaborating with healthcare professionals, Coloplast aims to improve the quality of life for patients worldwide. With its customer-centric approach, the company provides advanced medical solutions, education, and support to help individuals regain their independence and confidence. Coloplast A/S is committed to delivering high-quality products and services that empower individuals to live an active and fulfilling life.
Coloplast A/S is primarily active in the healthcare industry.
The main competitors of Coloplast A/S in the market include Medtronic, Hollister Incorporated, and Convatec.
Coloplast A/S is a renowned Danish medical device company specializing in developing and manufacturing products for ostomy care, urology, continence care, and wound care. Founded in 1957, Coloplast has established itself as a global leader in its field, serving patients in more than 140 countries. With a strong focus on innovation, Coloplast continuously strives to improve the quality of life for individuals with intimate healthcare needs. The company's success is attributed to its commitment to customer-centricity and its ability to anticipate and adapt to changing market demands. Over the years, Coloplast has consistently delivered innovative solutions and has built a reputation for providing exceptional products and services in the healthcare industry.
Coloplast A/S, a leading medical device company, has achieved several significant milestones throughout its history. The company has a strong track record of innovation and has consistently introduced groundbreaking products to the market. Coloplast A/S introduced the world's first disposable ostomy appliance in 1954, revolutionizing care for ostomy patients. In recent years, the company has focused on expanding its product portfolio in urology and continence care, bringing advanced solutions to patients suffering from bladder and bowel dysfunctions. With a commitment to improving the quality of life for individuals with intimate healthcare needs, Coloplast A/S continues to make strides in the medical device industry.
Coloplast A/S is primarily present in a diverse range of countries and regions worldwide. The company has a strong global presence, serving markets in Europe, North America, Latin America, Asia-Pacific, the Middle East, and Africa. With a focus on providing innovative medical solutions, Coloplast A/S has established its footprint in numerous countries, including the United States, Germany, France, China, Japan, Brazil, Australia, and South Africa. Through its widespread reach, Coloplast A/S ensures that its advanced healthcare products and services are accessible to patients and healthcare professionals across different regions, contributing to improved quality of life and better healthcare outcomes.
Coloplast A/S represents values of compassion, innovation, and responsibility in its corporate philosophy. As a global healthcare company specializing in medical products and services, Coloplast A/S is dedicated to improving the lives of individuals with intimate healthcare needs. The company emphasizes care and understanding towards its customers, striving to develop innovative solutions that enhance their quality of life. Coloplast A/S's commitment to responsible business practices is reflected in its focus on sustainability, ethics, and transparency. With its strong emphasis on compassion, innovation, and responsibility, Coloplast A/S stands as a leading healthcare company, providing essential products and services to improve the well-being of individuals worldwide.
Analysts currently set an average price target of 658.22 DKK for the Coloplast A/S stock (median: 642.60 DKK), implying +57.1 % versus the latest price. The consensus is based on 27 analyst ratings.
27 analysts currently rate the Coloplast A/S stock: 9 recommend buying, 16 holding and 2 selling. For 2026, analysts expect Coloplast A/S to generate revenue of 28.85 B DKK and earnings per share of 24.87 DKK.
Converted at the current exchange rate, the Coloplast A/S share trades at 56.05 EUR (419.00 DKK).
The Coloplast A/S share (COLO B.CO) is listed on 10 stock exchanges, including: London (0QBO.L), SIX (Zürich) (COLOB.SW), XETRA (CBHD.DE), Frankfurt (CBHD.F), München (CBHD.MU), Düsseldorf (CBHD.DU), Wien (COLO.VI), Kopenhagen (COLO-B.CO).
Coloplast A/S is a global company specializing in the development, manufacture, and distribution of medical devices and healthcare products. The company is divided into different business areas that focus on different customer needs. Its main business areas include continence care, wound care, and surgical products. Coloplast also offers products and services for animal continence care and wound care. The company is committed to providing high-quality products and improving patient care through innovation and collaboration with healthcare professionals. Coloplast operates in over 100 countries worldwide and strives to be a leading provider in the healthcare market.
The expected revenue of Coloplast A/S is 28.85 B DKK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Coloplast A/S is 5.60 B DKK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Coloplast A/S is currently 16.85. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Coloplast A/S stock.
The price-to-sales ratio (P/S) of Coloplast A/S is currently 3.27. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Coloplast A/S stock.
The Eulerpool Quality Score for Coloplast A/S is 8/10.
The ISIN of Coloplast A/S is DK0060448595. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Coloplast A/S is A1KAGC. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Coloplast A/S is COLO B.CO. The ticker symbol is used to trade Coloplast A/S shares on the stock exchange.
Coloplast A/S stock
Coloplast A/S Peer Group
Coloplast A/S Ticker
Coloplast A/S FIGI
All fundamentals and in-depth analysis of Coloplast A/S
Our stock analysis for Coloplast A/S stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Coloplast A/S. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.